Patent grant further strengthens POLB 001’s global intellectual property portfolio 6 October 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that a South Korean patent relating to POLB 001 has been formally granted. The patent, entitled “Medicinal products and methods for […]
Financing will be used to advance Rewind’s lead oral program designed to promote remyelination and restore neurological function Peer-reviewed data published in PLOS ONE demonstrated remyelination and functional recovery following oral treatment with a selective GPR17 antagonist in preclinical models Leuven, Belgium – 6 October 2026 – Rewind Therapeutics (“Rewind”), a biotechnology company developing small-molecule […]
Recognition reflects Freya’s scientific progress and commitment to addressing significant unmet needs in women’s health Copenhagen, Denmark and Boston, Massachusetts, 5 October 2026: Freya Biosciences (“Freya” or “the Company”), a clinical-stage immunology company developing therapies to treat inflammation and immune dysregulation in women, today announces that Fierce Biotech, a division of Forge, has named it […]
Lund, Sweden, October 2, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in the State of the Industry Panel at the 26th Annual Biotech in Europe Forum, on Wednesday 7 October, at 8:30 CEST, at the Mövenpick Hotel Basel, Switzerland. Read more…
Analysis of 3,918 adults across Germany, the Netherlands and France, with no eligibility criteria beyond active system use, covering 323,814 person-days of real-world experience Users achieved median time in range of2%, while median time below 54 mg/dL (3.0 mmol/L) was 0.21% – equivalent to approximately three minutes per day Median coefficient of variation of 28.7%, […]
